Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

number of downloads : ?

Use this link to cite this item : https://ir.lib.shimane-u.ac.jp/53573

language	eng
Author	Kinoshita, Yoshikazu Sakurai Yuuichi Takeda Development Center Japan, Takeda Pharmaceutical Company Ltd, Osaka, Japan Shiino Madoka Takeda Development Center Japan, Takeda Pharmaceutical Company Ltd, Osaka, Japan Kudou Kentaro Takeda Development Center Japan, Takeda Pharmaceutical Company Ltd, Osaka, Japan Nishimura Akira Takeda Development Center Japan, Takeda Pharmaceutical Company Ltd, Osaka, Japan Miyagi Takuya Department of Gastroenterology and Hepatology, Yao Municipal Hospital, Yao, Japan Iwakiri Katsuhiko Department of Gastroenterology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan Umegaki Eiji Department of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Japan Ashida Kiyoshi Department of Gastroenterology, Rakuwakai Otowa Hospital, Kyoto, Japan
Subject	gastroesophageal reflux; heartburn; NERD; nonerosive gastroesophageal reflux disease; potassium-competitive acid blockers; vonoprazan
Journal Title	CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
Volume	81-82
Start Page	1
End Page	7
ISSN	0011-393X
ISSN（Online）	1879-0313
Published Date	2016
DOI	10.1016/j.curtheres.2016.12.001
PubMed ID	28119763
Publisher	ELSEVIER SCIENCE INC
NII Type	Journal Article
OAI-PMH Set	Faculty of Medicine
Remark	This work was supported by Takeda Pharmaceutical Company Limited, manufacturer / licensee of vonoprazan. Medical writing assistance was provided by Elise Magatova, PhD, and Tania Dickson, PhD, of ProScribe - Envision Pharma Group, and was funded by Takeda Pharmaceutical Company Limited. ProScribe's services complied with international guidelines for Good Publication Practice (GPP3).